《新股消息》微泰醫療(02235.HK)公開超購5.79倍 一手中籤率80.01%
提供糖尿病治療及糖尿病監測醫療器械的生物科技企業微泰醫療(02235.HK)公佈招股結果,擬於全球發售6,352.95萬股,其中10%於本港作公開發售,本港公開發售部分錄得超額認購約5.79倍,每手100股計,一手中籤率爲80.01%,要認購兩手即100股纔可穩獲一手。該股將於明日(19日)掛牌。
每股發售價定爲30.5元,接近招股價27.7至31.15元的上限定價,公司預計,集資所得淨額約18.15億元,擬將31%分配予核心產品;35%分配予持續血糖監測系統;11%用於第二代貼敷式胰島素泵系統的臨牀前研究、臨牀試驗、註冊、生產及商業化;8%分配至其他產品及在研產品的臨牀前研究、臨牀試驗、註冊、生產及商業化;5%將用於爲建立公司基於雲端大數據的糖尿病管理平臺提供資金;及10%將分配用於營運資金及其他一般公司用途。
根據相關基石投資協議,公司的基石投資者已認購合共3,917.13萬股,佔公司已發行股本約9.2%。當中,Invesco Advisers, Inc.認購893.16萬股,佔上市後股本2.1%;UBS AM Singapore認購637.97萬股,佔上市後股本1.5%。
公司的聯席保薦人、聯席全球協調人、聯席帳簿管理人及聯席牽頭經辦人爲高盛及中金,聯席帳簿管理人及聯席牽頭經辦人爲中信證券。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.